BRK.B vs. JNJ: A Head-to-Head Stock Comparison

Updated on August 19, 2025

Here’s a clear look at BRK.B and JNJ, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	BRK.B	JNJ
Company Name	Berkshire Hathaway Inc.	Johnson & Johnson
Country	United States	United States
GICS Sector	Financials	Health Care
GICS Industry	Financial Services	Pharmaceuticals
Market Capitalization	1,029.25 billion USD	420.06 billion USD
Exchange	NYSE	NYSE
Listing Date	May 9, 1996	January 2, 1962
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of BRK.B and JNJ by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

BRK.B vs. JNJ: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	BRK.B	JNJ
5-Day Price Return	2.21%	1.68%
13-Week Price Return	-7.33%	13.16%
26-Week Price Return	0.09%	13.62%
52-Week Price Return	10.68%	9.09%
Month-to-Date Return	-0.61%	5.88%
Year-to-Date Return	5.08%	20.61%
10-Day Avg. Volume	0.00M	8.74M
3-Month Avg. Volume	0.00M	8.75M
3-Month Volatility	13.33%	20.14%
Beta	0.48	0.38

Profitability

Return on Equity (TTM)

BRK.B

9.68%

Financial Services Industry

Max: 40.58%
Q3: 20.06%
Median: 10.67%
Q1: 4.19%
Min: -10.31%

BRK.B’s Return on Equity of 9.68% is on par with the norm for the Financial Services industry, indicating its profitability relative to shareholder equity is typical for the sector.

JNJ

30.39%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

In the upper quartile for the Pharmaceuticals industry, JNJ’s Return on Equity of 30.39% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

BRK.B vs. JNJ: A comparison of their Return on Equity (TTM) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

BRK.B

17.00%

Financial Services Industry

Max: 52.86%
Q3: 25.58%
Median: 12.23%
Q1: 6.64%
Min: -9.92%

BRK.B’s Net Profit Margin of 17.00% is aligned with the median group of its peers in the Financial Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

JNJ

25.00%

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

A Net Profit Margin of 25.00% places JNJ in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

BRK.B vs. JNJ: A comparison of their Net Profit Margin (TTM) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

BRK.B

13.29%

Financial Services Industry

Max: 77.28%
Q3: 37.68%
Median: 18.17%
Q1: 9.27%
Min: -8.19%

BRK.B’s Operating Profit Margin of 13.29% is around the midpoint for the Financial Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

JNJ

30.18%

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

An Operating Profit Margin of 30.18% places JNJ in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

BRK.B vs. JNJ: A comparison of their Operating Profit Margin (TTM) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	BRK.B	JNJ
Return on Equity (TTM)	9.68%	30.39%
Return on Assets (TTM)	5.44%	12.16%
Net Profit Margin (TTM)	17.00%	25.00%
Operating Profit Margin (TTM)	13.29%	30.18%
Gross Profit Margin (TTM)	16.97%	67.98%

Financial Strength

Current Ratio (MRQ)

BRK.B

1.95

Financial Services Industry

Max: 4.58
Q3: 2.59
Median: 1.33
Q1: 0.69
Min: 0.01

For the Financial Services industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

JNJ

1.01

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

JNJ’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

BRK.B vs. JNJ: A comparison of their Current Ratio (MRQ) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

BRK.B

0.19

Financial Services Industry

Max: 4.96
Q3: 2.10
Median: 0.57
Q1: 0.12
Min: 0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Financial Services industry.

JNJ

0.65

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

JNJ’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

BRK.B vs. JNJ: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

BRK.B

0.57

Financial Services Industry

Max: 136.23
Q3: 56.08
Median: 6.55
Q1: 2.01
Min: -33.27

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Financial Services industry.

JNJ

34.01

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

JNJ’s Interest Coverage Ratio of 34.01 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

BRK.B vs. JNJ: A comparison of their Interest Coverage Ratio (TTM) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	BRK.B	JNJ
Current Ratio (MRQ)	1.95	1.01
Quick Ratio (MRQ)	1.68	0.68
Debt-to-Equity Ratio (MRQ)	0.19	0.65
Interest Coverage Ratio (TTM)	0.57	34.01

Growth

Revenue Growth

BRK.B vs. JNJ: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

BRK.B vs. JNJ: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

BRK.B

0.00%

Financial Services Industry

Max: 8.18%
Q3: 3.60%
Median: 1.56%
Q1: 0.00%
Min: 0.00%

BRK.B currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

JNJ

2.89%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

JNJ’s Dividend Yield of 2.89% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

BRK.B vs. JNJ: A comparison of their Dividend Yield (TTM) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

BRK.B

0.00%

Financial Services Industry

Max: 155.56%
Q3: 63.71%
Median: 18.08%
Q1: 0.00%
Min: 0.00%

BRK.B has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

JNJ

53.34%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

JNJ’s Dividend Payout Ratio of 53.34% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

BRK.B vs. JNJ: A comparison of their Dividend Payout Ratio (TTM) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	BRK.B	JNJ
Dividend Yield (TTM)	0.00%	2.89%
Dividend Payout Ratio (TTM)	0.00%	53.34%

Valuation

Price-to-Earnings Ratio (TTM)

BRK.B

16.37

Financial Services Industry

Max: 63.23
Q3: 32.10
Median: 14.41
Q1: 10.81
Min: 0.37

BRK.B’s P/E Ratio of 16.37 is within the middle range for the Financial Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

JNJ

18.47

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

JNJ’s P/E Ratio of 18.47 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

BRK.B vs. JNJ: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

BRK.B

2.78

Financial Services Industry

Max: 11.16
Q3: 5.45
Median: 2.61
Q1: 1.25
Min: 0.04

The P/S Ratio is often not a primary valuation tool in the Financial Services industry.

JNJ

4.62

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

JNJ’s P/S Ratio of 4.62 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

BRK.B vs. JNJ: A comparison of their Price-to-Sales Ratio (TTM) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

BRK.B

1.57

Financial Services Industry

Max: 7.09
Q3: 3.79
Median: 1.46
Q1: 0.83
Min: 0.04

BRK.B’s P/B Ratio of 1.57 is within the conventional range for the Financial Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

JNJ

4.68

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

JNJ’s P/B Ratio of 4.68 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

BRK.B vs. JNJ: A comparison of their Price-to-Book Ratio (MRQ) against their respective Financial Services and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	BRK.B	JNJ
Price-to-Earnings Ratio (TTM)	16.37	18.47
Price-to-Sales Ratio (TTM)	2.78	4.62
Price-to-Book Ratio (MRQ)	1.57	4.68
Price-to-Free Cash Flow Ratio (TTM)	86.95	22.56